Effect of an immunomodulatory regimen for cancer prevention: A case report

Wang,Wenbo; Wang,Wei; Liu,Bing; Suo,Zhuoyao; Zhou,Lin; Liu,Guangxian

doi:10.3892/mco.2016.1018

Effect of an immunomodulatory regimen for cancer prevention: A case report

Authors:
- Wenbo Wang
- Wei Wang
- Bing Liu
- Zhuoyao Suo
- Lin Zhou
- Guangxian Liu
View Affiliations

Affiliations: Chinese Medicine Department, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing 100071, P.R. China, Cancer Therapy Center, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing 100071, P.R. China
Published online on: September 14, 2016 https://doi.org/10.3892/mco.2016.1018
Pages: 540-544
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present case study, an immunomodulatory regimen for cancer prevention is reported. A patient with an abnormally high level of the tumor markers, carbohydrate antigen-724 (CA724), CA19-9 and carcinoembryonic antigen (CEA), although without any detectable tumor, was treated with an immunomodulatory therapy featuring an infusion of cytokine-induced autologous killer cells (CIKs) at the request of the patient. Following the therapy, the three tumor markers rapidly decreased to below the normal reference level, although there still were slight fluctuations within a narrow range frequently. The patient was monitored for 21 months to the present day and no abnormality was observed. The results indicated that this therapy may be applied as a novel strategy that is effective and reliable for cancer prevention. As there is no promising regimen for the prevention of malignancies to date, such a treatment may become a major cancer prophylactic regimen, particularly for patients who are at a high risk of cancer.

View Figures

View References

1	Cataldo VD, Gibbons DL, Pérez-Soler R and Quintás-Cardama A: Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 364:947–955. 2011. View Article : Google Scholar : PubMed/NCBI
2	Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
3	Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 262:3–11. 1991.PubMed/NCBI
4	Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 313:1485–1492. 1985. View Article : Google Scholar : PubMed/NCBI
5	Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, et al: Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN): Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol. 22:1188–1194. 2004. View Article : Google Scholar : PubMed/NCBI
6	Schuler G, Schuler-Thurner B and Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 15:138–147. 2003. View Article : Google Scholar : PubMed/NCBI
7	Finn OJ: Cancer vaccines: Between the idea and the reality. Nat Rev Immunol. 3:630–641. 2003. View Article : Google Scholar : PubMed/NCBI
8	Liu G, Yang W, Guo M, Liu X, Huang N, Li D, Jiang Z, Yang W, Zhang W, Su H, et al: Effective modulation of CD4(+)CD25 (+high) regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2. Cancer Immunol Immunother. 61:2357–2366. 2012. View Article : Google Scholar : PubMed/NCBI
9	Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
10	Rabinovich GA, Gabrilovich D and Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 25:267–296. 2007. View Article : Google Scholar : PubMed/NCBI
11	Valzasina B, Piconese S, Guiducci C and Colombo MP: Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. 66:4488–4495. 2006. View Article : Google Scholar : PubMed/NCBI
12	Jarnicki AG, Lysaght J, Todryk S and Mills KH: Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: Influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 177:896–904. 2006. View Article : Google Scholar : PubMed/NCBI
13	Vesely MD, Kershaw MH, Schreiber RD and Smyth MJ: Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 29:235–271. 2011. View Article : Google Scholar : PubMed/NCBI
14	Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:1107–1111. 2001. View Article : Google Scholar : PubMed/NCBI
15	Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
16	Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
17	Trzonkowski P, Szmit E, Myśliwska J, Dobyszuk A and Myśliwski A: CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol. 112:258–267. 2004. View Article : Google Scholar : PubMed/NCBI
18	Gattinoni L, Powell DJ Jr, Rosenberg SA and Restifo NP: Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol. 6:383–393. 2006. View Article : Google Scholar : PubMed/NCBI
19	Loeb LA, Loeb KR and Anderson JP: Multiple mutations and cancer. Proc Natl Acad Sci USA. 100:776–781. 2003. View Article : Google Scholar : PubMed/NCBI